Stock Track | Moderna Soars 5% as Government Renews COVID-19 Immunization Strategy

Stock Track

Oct 20

Moderna, Inc. (NASDAQ: MRNA) shares are soaring 5.02% in pre-market trading on Monday, following news of the government's renewed national immunization strategy to combat rising COVID-19 variants. This development has reignited investor interest in the biotechnology company, known for its mRNA-based vaccines.

The renewed focus on COVID-19 immunization comes at a crucial time for Moderna, as the company continues to adapt its vaccine technology to address emerging variants. This government initiative could potentially lead to increased demand for Moderna's COVID-19 vaccines and boosters, bolstering the company's revenue prospects.

While the stock is experiencing a significant uptick, it's worth noting that analysts remain cautious. Both Oppenheimer and Needham have recently reaffirmed their Hold ratings on Moderna stock. This suggests that while the immediate market reaction is positive, there may be lingering uncertainties about the company's long-term growth trajectory in a post-pandemic landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1139920085"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139920085\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139920085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139920085","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5% as Government Renews COVID-19 Immunization Strategy","media":"Stock Track","content":"<p>Moderna, Inc. (NASDAQ: MRNA) shares are soaring 5.02% in pre-market trading on Monday, following news of the government's renewed national immunization strategy to combat rising COVID-19 variants. This development has reignited investor interest in the biotechnology company, known for its mRNA-based vaccines.</p>\n\n<p>The renewed focus on COVID-19 immunization comes at a crucial time for Moderna, as the company continues to adapt its vaccine technology to address emerging variants. This government initiative could potentially lead to increased demand for Moderna's COVID-19 vaccines and boosters, bolstering the company's revenue prospects.</p>\n\n<p>While the stock is experiencing a significant uptick, it's worth noting that analysts remain cautious. Both Oppenheimer and Needham have recently reaffirmed their Hold ratings on Moderna stock. This suggests that while the immediate market reaction is positive, there may be lingering uncertainties about the company's long-term growth trajectory in a post-pandemic landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5% as Government Renews COVID-19 Immunization Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5% as Government Renews COVID-19 Immunization Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-20 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (NASDAQ: MRNA) shares are soaring 5.02% in pre-market trading on Monday, following news of the government's renewed national immunization strategy to combat rising COVID-19 variants. This development has reignited investor interest in the biotechnology company, known for its mRNA-based vaccines.</p>\n\n<p>The renewed focus on COVID-19 immunization comes at a crucial time for Moderna, as the company continues to adapt its vaccine technology to address emerging variants. This government initiative could potentially lead to increased demand for Moderna's COVID-19 vaccines and boosters, bolstering the company's revenue prospects.</p>\n\n<p>While the stock is experiencing a significant uptick, it's worth noting that analysts remain cautious. Both Oppenheimer and Needham have recently reaffirmed their Hold ratings on Moderna stock. This suggests that while the immediate market reaction is positive, there may be lingering uncertainties about the company's long-term growth trajectory in a post-pandemic landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1139920085","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139920085","pubTimestamp":1760969658,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (NASDAQ: MRNA) shares are soaring 5.02% in pre-market trading on Monday, following news of the government's renewed national immunization strategy to combat rising COVID-19 variants....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|政府更新新冠免疫策略Moderna大涨5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (NASDAQ: MRNA) shares are soaring 5.02% in pre-market trading on Monday, following news of the government's renewed national immunization strategy to combat rising COVID-19 variants. This development has reignited investor interest in the biotechnology company, known for its mRNA-based vaccines.\nThe renewed focus on COVID-19 immunization comes at a crucial time for Moderna, as the company continues to adapt its vaccine technology to address emerging variants. This government initiative could potentially lead to increased demand for Moderna's COVID-19 vaccines and boosters, bolstering the company's revenue prospects.\nWhile the stock is experiencing a significant uptick, it's worth noting that analysts remain cautious. Both Oppenheimer and Needham have recently reaffirmed their Hold ratings on Moderna stock. This suggests that while the immediate market reaction is positive, there may be lingering uncertainties about the company's long-term growth trajectory in a post-pandemic landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}